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The correspondence columns are an important feature of the SAMJ.
Letters are often shortened and, as with all text received, subject to
sub-editing to make them more reader-friendly. In the correspondence
concerning Mikulicz-Radecki, we erred in inadvertently printing an
explanatory covering letter to the Editor and not the correct response,
hence the author’s correction. — Ed.
To the Editor: The article by J Kowalczyk on the biography of
Professor Jan Mikulicz-Radecki1 made us analyse this subject
and we decided to compare it with our knowledge. In the years
1882 - 1887 Mikulicz-Radecki became a Director and Professor
of Surgery at Jagiellonian University in Kraków, Poland. In
1887 he became Director of the Clinic and Professor of Surgery
in Königsberg and afterwards in Wroclaw (Breslau).
Presumably Jan Mikulicz-Radecki belonged to both cultures
and nationalities: he was Polish by family origin and native
language, and German by his study and work in Vienna,
Königsberg and Wroclaw, as well as by his marriage to
Henrietta Pacher.
Mikulicz-Radecki was of course a famous surgeon, but we
would like to remind readers of his contribution to the
development of otorhinolaryngology. One of this earliest
articles was on scleroma and epidermoid cyst — one of the first
descriptions of cholesteatoma.2 In 1883 Mikulicz-Radecki gave
a method of radical resection of the tonsil carcinoma by lateral
pharyngotomy. He had led the section of the neck along the
margin of the sternocleidomastoid muscle, and subsequently
cut chewing muscles and resected the mandible body. In this
way he exposed the lateral wall of the pharynx and the whole
operation was done without opening the oral cavity and
pharynx.3 In 1886 he was the first to open the maxillary sinus
from the medial nasal meatus and to evacuate empyema from
the maxillary sinus. During his work in Kraków and Wroclaw
he constructed the skolizoymeter and more frequently used
Mikulicz’s compressorium and devices for intrathoracic
operations. He was the first to undertake an operation in a
large hypobaric chamber on a patient with neoplasm of the
upper part of the oesophagus.4 He published several articles on
the aseptics of surgical procedures and was a devotee of
iodoform usage. In 1892 Mikulicz-Radecki published work in
which he paid attention to disease with symmetrical, bilateral
oedema and enlargement of the salivary and lacrimal glands,
and to microscopic examination of lymphocyte infiltrations.
Later works described these symptoms as Mikulicz-Radecki
syndrome. In 1893 in Wroclaw Mikulicz-Radecki implanted a
glass faser wick from the ventricle through the subarachnoid
space to the galea, which was simultaneously the first
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The possibilities of hormone
replacement therapy started at
the critical time
To the Editor: In ‘Hormone replacement therapy — finally,
good data’,1 Rosenberg and Hoffman disagree with two recent
articles in the SAMJ2,3 as well as with Herrington et al.4 in the
Estrogen Replacement and Atherosclerosis (ERA) study who
state ‘Another possible explanation for our results are that
estrogen is more effective in preventing atherosclerosis than in
slowing the progression of the disease once it is established.’
To justify the idea that HRT is not protective against  heart
disease one of the three studies quoted1 is the Herrington ERA
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Fig. 1. Oesophagoscopy technique according to Mikulicz-Radecki
(from Mikulicz J. Ueber Gastroskopie und Oesophagoskopie. Wien
Med Presse 1881; 45: 1405-1408).
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study4 in which women (average age 65.8 years) with
angiographically verified coronary disease showed no
reduction in atherosclerosis but also no increase in clinical
cardiovascular disease.
It is agreed that randomised trials are the gold standard.1
They must, however, not be generalised to a population they
were not designed to study. Possible cardiovascular benefits of
HRT requires cardiovascularly healthy women with no
atherosclerosis within 5 - 10 years of the menopause3 before
downregulation of oestrogen receptors. This may also apply to
Alzheimer’s disease and dementia2 as demonstrated in the
Cache County study5 and the study by Resnick et al.6
This excludes the ERA study4 and a secondary prevention
study, viz. the Heart and Estrogen/Progestin Study (HERS).7
The third study quoted is the Women’s Health Initiative (WHI)8
which by design limited the intake of symptomatic women in
the early years of the menopause. Statistics from the follow-up9
show the hazard ratio (HR) of coronary heart disease (CHD) in
the first 10 years since the menopause to be 0.86 but not
statistically significant by 95% confidence interval (CI). But
then neither was the HR for CHD in the entire cohort  (HR
1.29, adjusted CI: 0.85 - 1.97).
Criticism of the statistics in the WHI is ongoing,3 with
Shapiro and Tucker10 having differing views.
Was the WHI Data and Safety Monitoring Board biased in
stopping the WHI trial mainly on the basis of breast cancer
harm? At baseline over 25% of the women were previous HRT
users, with about 12% of these women using HRT for more
than 10 years before the start of the WHI trial and about 6%
being current users. Exclusion of this group decreases the HR
from 1.26 to 1.06.
Is it biased to compare HRT users who had started HRT
prior to the commencement of the trial with placebo (average
duration 5.2 years) and then to suggest that breast cancers are
more advanced in the HRT group?11 The follow-up article does
not give a breakdown on previous versus no previous HRT
use.11
To support their argument Rosenberg and Hoffman1 also
use a pooled meta-analysis12 of 22 small (total 4 124), short-
duration (3 months - 3 years) trials of HRT use in mostly young
women where cardiovascular disease was a secondary
endpoint and had an odds ratio of 1.39 (CI: 0.48 - 3.59).
Rosenberg and Hoffman1 don’t mention that this pooled
analysis showed that the rate of breast cancer was lower in the
hormone group.12
Also not mentioned was a meta-analysis of 22 studies by
Barrett-Connor et al.13 up to 1997 which showed a relative risk
(RR) of 0.7 (CI: 0.65 - 0.75) for cardiovascular events in ‘ever-
users’ of mainly unopposed oestrogens over ‘never-users’. In 7
studies using opposed oestrogen, mainly medroxyprogesterone
acetate, the RR was 0.66 (CI: 0.53 - 0.84). Is one of the
oestrogens used in the Million Women Study (MWS)14 ethinyl
oestradiol, as suggested in Fig. 3? It has not been used for HRT
for many years. This trial differs from most other studies on
breast cancer, including the WHI.
Is it statistically correct, as in the MWS, to exclude women
with a history of breast cancer at baseline, total number
unknown, who had registered before recruitment? There were
485 breast cancer deaths reported in this excluded group, with
only 3% using HRT.14 As incident breast cancers were
diagnosed on average 1.2 years after recruitment and because
breast cancer generally requires several years (7 - 10) to grow to
a clinically or radiologically detectable size,15 it makes
biological as well as epidemiological sense to include this
group in the final analysis despite counter-suggestions by the
collaborators. There were 637 breast cancer deaths included in
the study summary and 517 in Fig. 6. Current users of HRT at
baseline had a RR of breast cancer of 1.22, which according to
the collaborators is of ‘borderline significance’.14 What would
the RR be if the excluded group was included?
Another MWS media headline ‘Oestrogen-progestogen
increases incident invasive breast cancer in year one’ is due to a
statistical variation used by the collaborators, and if  worked
out in the same way as the WHI and most other trials, i.e.
number of breast cancers in the whole cohort taking HRT for
that year(s) and not just  women using HRT in that year(s) only
as done in the MWS, the RR for less than 1 year is < 0.10, for 1 -
4 years 0.61, for 5 - 9 years 1.43, and for more than 10 years 2.08
— and not 1.45, 1.74, 2.17 and 2.31 as suggested by the
collaborators.14
Another statistic not in agreement with previously held
views is the RR of invasive breast cancer according to
menopausal status among never-users of HRT:14 premenopausal
women 1.00, perimenopausal women 0.75 (CI: 0.68 - 0.82) and
postmenopausal women 0.63 (CI: 0.58 - 6.8).
No trial has previously shown tibolone (Livifem) to increase
the risk of breast cancer, but in the MWS the RR is 1.45 (CI: 1.25
- 1.68) based on 184 cases, and 1.48 (1.20 - 1.83) based on 88
incident breast cancer patients who used tibolone exclusively.
A suggestion is that it is because of preferential prescribing
of tibolone for high-risk breast cancer women. Incident breast
cancer was diagnosed in tibilone and HRT users on average 
1 - 2 years after recruitment, suggesting the presence of cancer
at recruitment.
Tibolone and its metabolites are selective oestrogen enzyme
modulators (SEEM) and inhibit sulfatase and 17B-hydroxy-
steroid dehydrogenase in hormone-dependent breast cancer
cells as well as increasing sulfotransferase activity. Biologically,
therefore, it should decrease and not increase breast cancer risk.
What is required is a randomised case-controlled trial on a
population that may benefit from HRT, which may be women
in the first 5 - 10 years of the menopause, and assessment of
contraindications from this and previous trials.
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Possibly the results of the WHI would have been very
different if the contraindications to the HRT suggested3 had
been used.
The International Menopause Society Workshop position
statement of HRT (Vienna, December 2003) will be published
soon and will constitute an unbiased opinion by the world’s
experts.
R L Cheifitz
Christiaan Barnard Memorial Hospital
Cape Town
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Rosenberg and Hoffman reply: Dr Cheifitz criticises various
aspects of the Women's Health Initiative (WHI) (a randomised
controlled trial)1 and of the Million Women Study (an
observational study).2 Both indicate that combined
oestrogen/progestin therapy (HRT) increases the risk of breast
cancer.  Rather than respond to each of Dr Cheifitz’s comments,
we note that the weight of evidence that HRT causes breast
cancer is appreciable and comes from numerous studies, many
of excellent quality and with large sample sizes.3 Moreover, the
randomised trial data and observational data are in agreement.   
As for coronary heart disease (CHD), the randomised trials
indicate that HRT does not protect against  CHD in healthy
women,1 recurrent CHD,4 or progression of atherosclerosis.5
Indeed, the WHI and HERS trials suggest that risk of CHD is
increased acutely within a year or so after the beginning of
HRT use (which suggests a prothrombotic mechanism, which
may also account for the increases in deep-vein thrombosis and
stroke in HRT users).  Dr Cheifitz argues that the results of
these randomised trials on CHD should not be generalised to a
population that they were not designed to study, i.e. healthy
women with no atherosclerosis who are within 5 - 10 years of
their menopause.  He suggests that what is required is a
randomised controlled trial of HRT and CHD in such a
population.   However, in a trial among younger women, the
increased risk of breast cancer would come at a younger age
than the putative benefits against CHD, osteoporotic fractures,
and Alzheimer’s disease.1,6-9 Therefore, if such a trial were
found to be ethical and feasible among younger women, it
would probably be stopped early because of an excess of risk
over benefit.  
In our commentary we stated our belief that it is unjustified
to increase the risk of breast cancer, stroke, deep-vein
thrombosis and other serious diseases in healthy women in
order to decrease their risk of other illnesses.10 It is even more
unjustified when the risks come at an earlier age than the
proposed benefits, and when there are other proven safer ways
of disease prevention.
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